tetano
Editor, Senior Moderator
Pharmacol Rep
. 2020 Aug 20.
doi: 10.1007/s43440-020-00152-9. Online ahead of print.
Pharmacological treatments of COVID-19
Adeleh Sahebnasagh[SUP] 1 [/SUP], Razieh Avan[SUP] 2 [/SUP], Fatemeh Saghafi[SUP] 3 [/SUP], Mojataba Mojtahedzadeh[SUP] 4 [/SUP], Afsaneh Sadremomtaz[SUP] 5 [/SUP], Omid Arasteh[SUP] 6 [/SUP], Asal Tanzifi[SUP] 7 8 [/SUP], Fatemeh Faramarzi[SUP] 9 [/SUP], Reza Negarandeh[SUP] 10 [/SUP], Mohammadreza Safdari[SUP] 11 [/SUP], Masoud Khataminia[SUP] 12 [/SUP], Hassan Rezai Ghaleno[SUP] 13 [/SUP], Solomon Habtemariam[SUP] 14 [/SUP], Amirhosein Khoshi[SUP] 15 [/SUP]
Affiliations
Abstract
The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies.
Keywords: COVID-19; Pharmacology; Pneumonia; SARS-CoV2.
. 2020 Aug 20.
doi: 10.1007/s43440-020-00152-9. Online ahead of print.
Pharmacological treatments of COVID-19
Adeleh Sahebnasagh[SUP] 1 [/SUP], Razieh Avan[SUP] 2 [/SUP], Fatemeh Saghafi[SUP] 3 [/SUP], Mojataba Mojtahedzadeh[SUP] 4 [/SUP], Afsaneh Sadremomtaz[SUP] 5 [/SUP], Omid Arasteh[SUP] 6 [/SUP], Asal Tanzifi[SUP] 7 8 [/SUP], Fatemeh Faramarzi[SUP] 9 [/SUP], Reza Negarandeh[SUP] 10 [/SUP], Mohammadreza Safdari[SUP] 11 [/SUP], Masoud Khataminia[SUP] 12 [/SUP], Hassan Rezai Ghaleno[SUP] 13 [/SUP], Solomon Habtemariam[SUP] 14 [/SUP], Amirhosein Khoshi[SUP] 15 [/SUP]
Affiliations
- PMID: 32816200
- DOI: 10.1007/s43440-020-00152-9
Abstract
The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies.
Keywords: COVID-19; Pharmacology; Pneumonia; SARS-CoV2.